Natural Capsules
- Market cap
- ₹ 162 Cr.
- P/E
- 194.3x
- P/B
- 0.89x
- 52-week range
- 132.02 – 234
- ROE
- −9%
- ROCE
- −5%
- Dividend yield
- 0%
- Debt / equity
- 0.5
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Natural Capsules Limited is an India-based hard capsule shell manufacturer, specialized in manufacturing an array of capsules, including hard gelatin capsules, vegetarian capsules, and various specialty variants. The Company offers a diverse range of capsule products to both domestic and international markets, serving the pharmaceutical and nutraceutical industries. Its offerings include hard gelatin capsules, hydroxypropyl methylcellulose (HPMC) vegetarian capsules and others, including shiny capsules, sweet capsules, fast-release capsules, regulatory variants, sodium laureth sulfate (SLS) free capsules, preservative free capsules and transmissible spongiform encephalopathy (TSE) free capsules. The Company, through its subsidiary, Natural Biogenex Private Limited, is focused on manufacturing APIs such as prednisolone, betamethasone, dexamethasone, and hydrocortisone along with their derivatives. It has two manufacturing facilities that are located in Bengaluru and Puducherry.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Natural Capsules against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)194.3 against a typical 34.3: pricier than most peers (1st = cheapest).206th of 220
- Sales growth+7.8% against a typical +15.6% from a year earlier.123rd of 197
- Share price, 3 months−4.3% against a typical 0%.118th of 200
- Size₹ 162.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).129th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BB+ by Infomerics- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Infomerics | IVR BB+ | Stable | 19 Mar 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 19 Mar 2026 | New rating | IVR BB+ | — | Infomerics | ₹ 59.15 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 2 Sep 2026 | Fund Raising | To consider Fund Raising |
| 12 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 27 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 13 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 13 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 4 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 38 | 40 | 40 | 39 | 41 | 44 | 45 | 45 | 46 | 38 | 58 | 49 |
| Expenses | 32 | 35 | 36 | 35 | 37 | 40 | 41 | 45 | 47 | 40 | 57 | 48 |
| Operating Profit | 5 | 5 | 4 | 4 | 5 | 4 | 4 | 0 | −1 | −2 | 1 | 1 |
| OPM % | 13.7% | 11.8% | 10.2% | 11.2% | 10.9% | 9.7% | 9.8% | 0.7% | −1.9% | −6.2% | 2.3% | 2.3% |
| Other Income | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Interest | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 5 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | 2 | 2 | 1 | 1 | 1 | 1 | 1 | −6 | −8 | −9 | −5 | −6 |
| Tax % | 27.1% | 33% | 32.2% | 21.8% | 201.6% | 78.4% | 41.6% | −8.1% | −9.1% | −21.7% | −2% | −1.5% |
| Net Profit | 2 | 1 | 1 | 1 | −1 | 0 | 1 | −6 | −7 | −7 | −5 | −6 |
| EPS in Rs | 1.68 | 1.3 | 1.04 | 0.64 | −0.6 | 0.11 | 0.35 | −5.4 | −6.76 | −4.77 | −3.32 | −3.82 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 19%
- 3 Years
- 3%
- TTM
- 9%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −238%
- 10 Years
- 8%
- 5 Years
- 2%
- 3 Years
- −25%
- TTM
- —
- 10 Years
- —
- 5 Years
- 3%
- 3 Years
- −2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Natural Capsules | ₹ 138.00 | ₹ 162 Cr. | 194.3x | 0.9x | −9% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Prasanna Junnarkar
- Chief Financial Officer
- Sunil L. Mundra
- Managing Director, Executive Director
- Laxminarayan Moondra
- Whole-time Director
- Satyanarayan Mundra
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.